Long-term effect of trastuzumab on QT dispersion in adjuvant treatment for patients with Her2 receptor positive breast cancer: A pilot study

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3265-3271

  Tanriverdi, Ozgur ^a   Meydan, Nezih ^b   Barutca, Sabri ^b  

^a MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^b ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Arrhythmias; Cardiotoxicity; QT dispersion; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EARLY CANCER; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; RR INTERVAL; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; ELECTROCARDIOGRAPHY; HEART; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOTHERAPY; RETROSPECTIVE STUDY; TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; ELECTROCARDIOGRAPHY; EPIRUBICIN; FEMALE; HEART; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PILOT PROJECTS; RADIOTHERAPY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TIME;

EID: 84880252037     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0291-z     Document Type: Article

References (18)

1. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-33.
2. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004;22:322-8.
3. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-12.
4. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23:391-409.
5. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910-6.
6. Yavas O, Yazici M, Eren O, Oyan B. The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Med Wkly. 2007;137:556-8.
7. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27:5838-47.
8. Mozos I, Serban C. The relation between QT interval and T-wave variables in hypertensive patients. J Pharm Bioallied Sci. 2011;3:339-44.
9. Kautzer J, Yi G, Camm AJ, Malik M. Short and long term reproducibility of QT, QTc and QT dispersion measurement in healthy subjects. Pacing Clin Electrophysiol. 1994;17:928-37.
10. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-31.
11. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
12. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4 year follow-up of a randomized controlled trial. Lancet Oncol. 2011;12:236-44.
13. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:173-83.
14. Smith KL, Dang C, Seidman AD. Cardiac dysfunction associated with trastuzumab. Expert Opin Drug Saf. 2006;5:619-29.
15. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-6.
16. Tanriverdi O, Cetin D. Trastuzumab and QT dispersion: letter to the editor. Swiss Med Wkly. 2011;141:w13257.
17. Chein KR. Hereptin and the heart: a molecular modifier of cardiac failure. N Engl J Med. 2006;354:789-90.
18. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer. 2002;95:1592-600.